Novo’s once-daily sickle cell pill hits milestone. A smaller rival is sinking 24%.

Novo Nordisk says it plans to apply for regulatory approval of its sickle cell disease, etavopivat, in the second half of ...

$3 million prize goes to duo whose research led to first sickle cell CRISPR therapy

Dr. Swee Lay Thein and Dr. Stuart Orkin won the $3 million Breakthrough Prize in Life Sciences for their work toward a ...
Fierce Biotech

Novo readies SCD drug from $1.1B Forma buyout for approval push after phase 3 win

Novo Nordisk is gearing up to submit its rare blood disorder drug to the FDA after the former Forma Therapeutics asset ...
BioSpace

Novo’s late-stage sickle cell win piles pressure on competitors

Novo Nordisk’s etavopivat elicited a 27% drop in vaso-occlusive crises and 48.7% hemoglobin response after 24 weeks, creating ...

Novo posts late-stage trial win for sickle cell disease therapy

Novo Nordisk (NVO) announced on Monday that its HIBISCUS pivotal Phase 3 trial for etavopivat, an experimental therapy for ...

Novo Nordisk to seek oral sickle cell therapy approval after Phase III victory

Novo Nordisk will be happy with the results after Pfizer has dropped two SCD assets in recent years. Credit: JHVEPhoto / ...
WUFT

Medicaid has a new way to pay for costly sickle cell treatment: Only if it works

Serenity Cole enjoyed Christmas last month relaxing with her family near her St. Louis home, making crafts and visiting friends. It was a contrast to how Cole, 18, spent part of the 2024 holiday ...

Georgia lawmakers pass Sickle Cell Disease Protection Act, expanding care for thousands statewide

HB 334 heads to Gov. Kemp's desk, aiming to align Medicaid coverage for sickle cell and address disparities impacting Black ...
Houston Public Media

Medicaid has a new way to pay for costly sickle cell treatment: Only if it works

Serenity Cole lives in St. Louis with her grandmother, Theresa Cole. Serenity is doing well after being one of the first patients to get a gene therapy treatment for sickle cell disease under a new ...